سعر Angioblock 150/12.5 mg 21 film-coated tablets 2026

Fixed-dose oral film-coated tablets of irbesartan 150 mg and hydrochlorothiazide 12.5 mg (Angioblock, Global Napi Pharmaceuticals/GAP, Egypt); 21 tablets per pack.

• Hypertension, including patients not adequately controlled on monotherapy and as initial therapy in patients likely to need multiple drugs to reach blood-pressure goalsPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Adverse events more frequent than placebo (≥1%): dizziness (8%), fatigue (6%), musculoskeletal pain, nausea/vomiting, influenza, oedema, chest pain, abdominal pain, dyspepsia, orthostatic dizziness, tachycardia, abnormal urination.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Postmarketing: thrombocytopenia, hepatitis, jaundice, impaired renal function, urticaria, angioedema, anaphylaxis, hyperkalaemia, hypoglycaemia in diabetics, acute angle-closure glaucoma, non-melanoma skin cancer.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Anuria or hypersensitivity to other sulfonamide-derived drugs (hydrochlorothiazide component).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Coadministration with aliskiren in patients with diabetes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - fetal toxicity: drugs acting on the renin-angiotensin system can cause injury and death to the developing fetus; discontinue as soon as pregnancy is detected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Symptomatic hypotension in volume- or salt-depleted patients; correct depletion before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Electrolyte and metabolic disturbances: hypokalaemia, hyponatraemia, hypomagnesaemia or hyperkalaemia; hyperuricaemia/gout; altered glucose tolerance; raised cholesterol and triglycerides; hypercalcaemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Aliskiren, ACE inhibitors, other ARBs (dual RAS blockade)Increased risk of hypotension, hyperkalaemia and renal impairment; avoid combined RAS inhibitors; aliskiren contraindicated in diabetes and to be avoided if GFR <60 mL/min.DailyMed (U.S. National Library of Medicine)
• Potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutesRisk of hyperkalaemia; monitor serum potassium.DailyMed (U.S. National Library of Medicine)
• LithiumIncreased lithium levels and toxicity; monitor lithium levels.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: use of drugs acting on the renin-angiotensin system in the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death; discontinue as soon as pregnancy is detected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on irbesartan in human milk (present in rat milk); thiazides appear in human milk. Breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.